Skip to content
Heart icon (animated) heart icon (static)
Our Stories
Explore more Johnson & Johnson sites:


At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Infectious Diseases and Vaccines, Oncology, Immunology, Neuroscience, Pulmonary Hypertension, and Cardiovascular and Metabolism.
    • Infectious Diseases and Vaccines

      At Janssen, our fight against infectious diseases is a global effort. From viral hepatitis and human immunodeficiency virus (HIV) to pathogens of global concern. We strive to discover and develop novel therapeutics and vaccines to help prevent, treat and utlimately cure infectious diseases worldwide, improving treatment outcomes and patients’ lives.

      With goals like these, there’s no time to waste. That’s why the team focuses on internal discovery and world-class development of therapeutics and vaccines whilst seeking out partnerships across the world to connect our expertise with others. We believe these problems can be conquered the same way all of humanity’s greatest problems have been solved: persistent effort and game-changing innovation.

      Visit the Janssen Website
    • Oncology

      We envision a world where cancer is a preventable, chronic or curable disease. To get there, we’re focused on pursuing new pathways that can help to prolong and improve patient lives.

      In Oncology, our goal is to fundamentally alter the way cancer is understood, diagnosed, and managed. One of the innovative ways that we approach this challenge is via cancer interception. We are striving to achieve a more robust understanding of the mechanisms underlying the transition of normal cells to a pre-malignant state, with the goal of developing products capable of intercepting cancer at its earliest stages, when patients are healthier and more likely to benefit.

      Visit the Janssen Website
      Testimonal Image
      Circular image
      We envision a world where cancer is a preventable or curable disease. To get there, we're focusing on transformational science that will allow patients to live longer and better lives.
      — Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology
      Testimonial Image
    • Immunology

      Over the past decade, Janssen has redefined the standard of care in immunology. With a rich heritage in developing cutting-edge treatments that can help to address the needs of millions of patients living with autoimmune and inflammatory diseases. Janssen strives to change the way diseases are treated; pursuing new pathways that could prevent, intercept and ultimately cure, and expanding our portfolio beyond monoclonal antibodies to include novel, oral small molecules and new biologic platforms. Through our ongoing efforts in discovery, biomarkers, clinical research and external innovation, we are poised for continued leadership, bringing transformational medicines to patients and healthcare providers to achieve our vision: a world free from immune diseases.

    • Neuroscience

      At Janssen, we are focused on pushing the boundaries of medicine- to help resolve some of the most challenging medical conditions of our time. Mental health has been an important part of our heritage since our company was founded and we remain committed to reducing the burden, disability and devastation caused by mental health disorders.

      We continue to invest in expanding treatment options, even as many companies have moved away from neuroscience because of its complexity and risk. We are immensely proud of the many ground-breaking mental health products Janssen has pioneered over the course of our 60+ year legacy in field.

      Testimonal Image
      Circular image
      Janssen is leading efforts to discover and develop innovative therapeutic solutions for people with brain disorders and to eliminate the social stigma about these diseases.
      — Bill Martin, Ph.D., Global Therapeutic Head, Neuroscience
      Testimonial Image
    • Pulmonary Hypertension

      The integration of Actelion into the Janssen Pharmaceutical Companies of Johnson & Johnson in 2017, saw PH established as our sixth disease area strong hold. We aim to build upon the strong heritage of Actelion, where in the past two decades, the prognosis and quality of life for people with PH has significantly improved.

      Together, we have a clear strategy to transform lives through closing the diagnosis gap and building an innovative pipeline. Janssen is committed to improving PH patient outcomes for the long haul. This means holistically addressing unmet needs across the patient journey, including faster diagnosis, better monitoring and new treatment approaches, including novel therapeutic devices, digital health solutions and non-invasive diagnostics to aid faster referral to specialist care.

      Visit the Janssen Website
      Testimonal Image
      Circular image
      Our vision is a world free from immune diseases. To achieve this, we will translate internal and external science to deliver products that treat, cure, intercept, and prevent immune-mediated diseases.
      — David M. Lee, M.D., Ph.D., Global Therapeutic Area Head, Immunology
      Testimonial Image
    • Cardiovascular and Metabolism

      Janssen has an enduring commitment to researching the prevention and treatment of cardiovascular and metabolic diseases. Our aim is to develop innovative healthcare solutions that will significantly improve outcome for patients. As such, we are building a comprehensive approach to diabetes care as well as cardiovascular disease, uncovering new therapies we hope will improve the quality of life for patients.

      Our mission is global, local and personal. Together, we can reshape the future of cardiovascular and metabolic disease prevention and treatment.

      Testimonal Image
      Circular image
      Our deep scientific expertise and clinical development capabilities support our commitment to aggressively develop and launch transformational therapies for patients with cardiovascular and metabolic diseases.
      — James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism
      Testimonial Image

Pharmaceutical Products: 135 Years of Innovation

The First Family Planning Product

Ortho-Gynol was introduced in 1931 as the first prescription family planning product from the Ortho Products operating unit. This pioneering contraceptive gel was based on the need for trusted family planning products.

A New Standard for Treating Schizophrenia

HALDOL® (haloperidol) was discovered by Janssen Pharmaceutica, N.V. in 1960. Patients taking HALDOL® could be treated at home instead of in an institution. It became the gold standard for treating schizophrenia for more than 25 years.

Birth Control Options

Ortho Pharmaceutical introduces the second oral contraceptive available in the United States (Ortho-Novum 10 and Ortho-Novum 2, produced by Syntex).

Tackling Rh Hemolytic Disease

Ortho Diagnostic Systems introduces RhoGAM Rho(D) immune globulin, the first medication developed to prevent Rh hemolytic disease of the newborn.

Making Vaccines Affordable for the Whole World

We introduced a cell line technology that enables faster and most cost effective discovery, development and production of a range of potentially transformational vaccines and monoclonal antibodies.

Treating Anemia

PROCRIT®, approved by the U.S. FDA for use in 1989, is a prescription medicine used to treat certain types of anemia.

A New Treatment for Auto-immune Conditions

Centocor, now part of Janssen Biotech Inc., introduces REMICADE®, a prescription medication used to treat many auto-immune conditions, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and plaque psoriasis.

Hope for Preventing Ebola

AdVac® technology, based on the development and production of adenovirus vectors is introduced. It can be used to develop vaccines against life-threatening infectious diseases such as Ebola.

Johnson & Johnson Creates The Dr. Paul Janssen Award for Biomedical Research

Established in celebration of the legacy of “Dr. Paul” and in recognition of current researchers demonstrating a similar spirit, the Dr. Paul Janssen Award was first presented in 2006.

Prostate Cancer Options

ZYTIGA®, a prescription medication used in combination with prednisone to treat men with metastatic castration-resistant prostate cancer, is introduced.

DARZALEX® Launches

DARZALEX® (daratumumab) injection for intravenous infusion is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy.

WHO Essential Medicines

Eleven Janssen products are on the WHO Model List of Essential Medicines.


Circular image


Circular image


Circular image


Circular image


Circular image


Circular image


Circular image


Circular image


Circular image


Circular image


Circular image


Circular image

We Value Your Privacy

We use cookies to allow our site to work properly and to analyse our traffic. Data may be shared with our partners involved in the delivery and/or personalization of ads on elsewhere online as explained in Cookie settings.

Please click “Accept” if you agree to our use of cookies, "Cookie Settings" to manage your preferences, or “Reject” if you only agree to necessary cookies.

This website content is only aimed at residents in the United Kingdom.
Close cookie banner icon
Back to top
You are now leaving This link will take you to a website where the Privacy policy does not apply.